Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T19:03:44.686Z.
Calculation as of: 2026-10-06T19:03:44.686Z.
Quote observation: 2026-10-06T18:58:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f2b785bc55096390182f69d3a0e2d020d3bb9b84e75505e860cfcb21a76503d6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
TriSalus Life Sciences, Inc.
Market Cap
$271.54M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$271.00M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$272.44M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$270.31M
Free Cash Flow Yield
N/A
TTM Avg
11.89%
3Y Avg
9.26%
5Y Avg
7.84%
Market Cap
$270.26M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$270.23M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$266.63M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$265.39M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.94M
Free Cash Flow Yield
N/A
TTM Avg
2.40%
3Y Avg
2.40%
5Y Avg
2.40%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TriSalus Life Sciences, Inc. (TLSI) | $271.54M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $271.00M | N/A | N/A | N/A | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $272.44M | N/A | N/A | N/A | N/A |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.31M | N/A | 11.89% | 9.26% | 7.84% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $270.26M | N/A | N/A | N/A | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $270.23M | N/A | N/A | N/A | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $266.63M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $265.39M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.94M | N/A | 2.40% | 2.40% | 2.40% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.10M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
